ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1216

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare

Smitha Reddy1, Ray Mabaquiao 2 and Lisa Misell 3, 1Arthritis Care and Research Inc., Poway, CA, 2Triwest Research, El Cajon, CA, 3Dyve Biosciences, San Diego, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: crystal-induced arthritis and medication, gout, pain, Sodium Urate Crystals

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints.  Uric acid crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalization agents, such as sodium bicarbonate, to treat gout. Theoretically, an alkalinizing agent such as sodium bicarbonate (baking soda) may increase the systemic and/or local pH and may allow pH sensitive uric acid crystals to dissolve resulting in temporary relief of pain and shortening duration of a gout flare, however oral sodium bicarbonate use causes intolerable gastrointestinal side-effects.  Purpose of study was to determine if sodium bicarbonate in a patented transdermal drug delivery system can effectively and safely reduce pain and shorten duration of an acute gout flare.  This delivery system has been shown to effectively deliver sodium bicarbonate transdermally in prior animal and human studies.

Methods: This pilot study is prospective, double-blinded, randomized, and placebo-controlled in design.  Twenty-four subjects, female and male, aged 18+, with clinical diagnosis of gout, history of uric acid >6.8mg/dl, on stable medication regimen, presenting in clinic within 36 hours of initiation of acute gout attack and prescribed 0.6 mg/daily colchicine were included. Exclusion criteria included >stage 3 kidney disease, tophaceous gout, and recent/concurrent initiation of other pain medications (e.g. NSAID, corticosterioids).  Subjects were randomized to receive placebo lotion or sodium bicarbonate transdermal lotion (33% sodium bicarbonate and 0.5% menthol) and instructed to apply to the entire limb of up to three affected joints (target joint and up to two other joints).   Outcome measures included pain (numeric rating scale, 0-10), time to resolution (50% reduction in pain), range of motion and subject satisfaction. Time-points were baseline,15 & 30 min, and 1,2,4,6,8,10,12, and 14 days.  Adverse events were collected. Statistical analysis was repeated measures ANOVA with p< 0.05 as significant.

Results: The active treatment subjects (N=12) had pain scores that averaged about 1.3 points lower than the placebo patients (N=12) (p=0.004).  The figure shows the % reduction in pain scores over time in the target joint. The secondary joint (N=9 for both groups) also had a significant (p=0.04) reduction in pain with average pain of 1.2 points lower than control.  The mean time to resolution for the target joint was 4.1 days in placebo group and 2.2 days in the active group.  The mean time to resolution for the secondary joint was 2.8 days in the control group and 1.6 days in the active group.  Among those who attained improved ROM, average time was 2.5 days in placebo group and 1.7 days in active group.  No treatment related adverse events reported.

Conclusion: Topical transdermal sodium bicarbonate lotion use resulted in a highly significant (p=0.004) reduction in pain, as early as 15 min, and may speed resolution of acute gout attacks and improvement of range of motion.

Figure 1. The active treatment subjects -N=12- had pain scores that averaged about 1.3 points lower than the placebo patients -N=12- -p=0.0041-. The figure shows the % reduction in pain scores over time in the target joint.


Disclosure: S. Reddy, None; R. Mabaquiao, None; L. Misell, Dyve Biosciences, 3, 4.

To cite this abstract in AMA style:

Reddy S, Mabaquiao R, Misell L. Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pilot-randomized-double-blinded-placebo-controlled-efficacy-andsafety-study-of-a-transdermal-alkalinizing-and-pain-relieving-treatment-foracute-gout-flare/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pilot-randomized-double-blinded-placebo-controlled-efficacy-andsafety-study-of-a-transdermal-alkalinizing-and-pain-relieving-treatment-foracute-gout-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology